FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W347839190> ?p ?o ?g. }

• W347839190 endingPage "57" @default.
• W347839190 startingPage "50" @default.
• W347839190 abstract "Limited data exist to guide the use of androgen deprivation therapy (ADT) for men treated with radiation therapy (RT) after radical prostatectomy (RP). The optimal duration of ADT in this setting is unknown.To determine if the duration of ADT influences clinical outcomes for men receiving post-RP RT.A total of 680 men who received adjuvant radiation therapy (n=105) or salvage radiation therapy (n=575) between 1986 and 2010 at a single tertiary care institution were reviewed retrospectively. Median follow-up post-RT was 57.8 mo.RT was delivered using three-dimensional conformal or intensity-modulated RT in 1.8-Gy fractions. For patients treated with ADT, >80% were treated with a gonadotropin-releasing hormone agonist with or without a nonsteroidal antiandrogen.Biochemical failure (BF), distant metastasis (DM), prostate cancer-specific mortality (PCSM), and overall mortality were assessed using Kaplan-Meier analysis and propensity score analysis.Overall, 144 patients (21%) received ADT with post-RP RT, most of whom had high-risk disease features such as Gleason score 8-10, seminal vesicle invasion, or pre-RT prostate-specific antigen >1 ng/ml. Median ADT duration was 12 mo (interquartile range: 6.0-23.7). Patients who received <12 mo of ADT had an association with increased BF (hazard ratio [HR]: 2.27; p=0.003) and DM (HR: 2.48; p=0.03) compared with patients receiving ≥12 mo of ADT. The 5-yr rates of DM were 6.0% and 23% for ≥12 and <12 mo of ADT, respectively. On propensity score analysis controlling for pretreatment and treatment-related factors, each month of ADT was associated with a decreased risk for BF (HR: 0.95; p=0.0004), DM (HR: 0.88; p=0.0004), and PCSM (HR: 0.90; p=0.037). These findings are limited by the retrospective nature of our analysis.For men with high-risk disease features receiving ADT with post-RP RT, the duration of ADT is associated with clinical outcomes. Our findings suggest that for these men an extended course of ADT ≥12 mo may be preferable. Validation of our findings is needed.We evaluated outcomes for men with high-risk disease features treated with androgen deprivation therapy (ADT) and radiotherapy after radical prostatectomy. Longer durations of ADT resulted in improved patient outcomes." @default.
• W347839190 created "2016-06-24" @default.
• W347839190 creator A5000908221 @default.
• W347839190 creator A5020006331 @default.
• W347839190 creator A5021153217 @default.
• W347839190 creator A5038761649 @default.
• W347839190 creator A5045162411 @default.
• W347839190 creator A5056193789 @default.
• W347839190 creator A5056372279 @default.
• W347839190 creator A5060316016 @default.
• W347839190 creator A5073099461 @default.
• W347839190 date "2016-01-01" @default.
• W347839190 modified "2023-09-27" @default.
• W347839190 title "Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy" @default.
• W347839190 cites W1972256280 @default.
• W347839190 cites W1985587689 @default.
• W347839190 cites W1986114421 @default.
• W347839190 cites W2074421032 @default.
• W347839190 cites W2081224952 @default.
• W347839190 cites W2090176734 @default.
• W347839190 cites W2091371349 @default.
• W347839190 cites W2098903169 @default.
• W347839190 cites W2100001148 @default.
• W347839190 cites W2106285196 @default.
• W347839190 cites W2107671263 @default.
• W347839190 cites W2108864389 @default.
• W347839190 cites W2119979376 @default.
• W347839190 cites W2120160519 @default.
• W347839190 cites W2132972168 @default.
• W347839190 cites W2137615050 @default.
• W347839190 cites W2142359566 @default.
• W347839190 cites W2144168223 @default.
• W347839190 cites W2148195102 @default.
• W347839190 cites W2148386014 @default.
• W347839190 cites W2148539277 @default.
• W347839190 cites W2159790321 @default.
• W347839190 doi "https://doi.org/10.1016/j.eururo.2015.05.009" @default.
• W347839190 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26004800" @default.
• W347839190 hasPublicationYear "2016" @default.
• W347839190 type Work @default.
• W347839190 sameAs 347839190 @default.
• W347839190 citedByCount "30" @default.
• W347839190 countsByYear W3478391902015 @default.
• W347839190 countsByYear W3478391902016 @default.
• W347839190 countsByYear W3478391902017 @default.
• W347839190 countsByYear W3478391902018 @default.
• W347839190 countsByYear W3478391902019 @default.
• W347839190 countsByYear W3478391902020 @default.
• W347839190 countsByYear W3478391902021 @default.
• W347839190 countsByYear W3478391902022 @default.
• W347839190 countsByYear W3478391902023 @default.
• W347839190 crossrefType "journal-article" @default.
• W347839190 hasAuthorship W347839190A5000908221 @default.
• W347839190 hasAuthorship W347839190A5020006331 @default.
• W347839190 hasAuthorship W347839190A5021153217 @default.
• W347839190 hasAuthorship W347839190A5038761649 @default.
• W347839190 hasAuthorship W347839190A5045162411 @default.
• W347839190 hasAuthorship W347839190A5056193789 @default.
• W347839190 hasAuthorship W347839190A5056372279 @default.
• W347839190 hasAuthorship W347839190A5060316016 @default.
• W347839190 hasAuthorship W347839190A5073099461 @default.
• W347839190 hasConcept C119060515 @default.
• W347839190 hasConcept C121608353 @default.
• W347839190 hasConcept C126322002 @default.
• W347839190 hasConcept C126894567 @default.
• W347839190 hasConcept C17923572 @default.
• W347839190 hasConcept C207103383 @default.
• W347839190 hasConcept C2776694085 @default.
• W347839190 hasConcept C2777899217 @default.
• W347839190 hasConcept C2779322244 @default.
• W347839190 hasConcept C2779466945 @default.
• W347839190 hasConcept C2780192828 @default.
• W347839190 hasConcept C2780775027 @default.
• W347839190 hasConcept C2781406297 @default.
• W347839190 hasConcept C44249647 @default.
• W347839190 hasConcept C509974204 @default.
• W347839190 hasConcept C71924100 @default.
• W347839190 hasConceptScore W347839190C119060515 @default.
• W347839190 hasConceptScore W347839190C121608353 @default.
• W347839190 hasConceptScore W347839190C126322002 @default.
• W347839190 hasConceptScore W347839190C126894567 @default.
• W347839190 hasConceptScore W347839190C17923572 @default.
• W347839190 hasConceptScore W347839190C207103383 @default.
• W347839190 hasConceptScore W347839190C2776694085 @default.
• W347839190 hasConceptScore W347839190C2777899217 @default.
• W347839190 hasConceptScore W347839190C2779322244 @default.
• W347839190 hasConceptScore W347839190C2779466945 @default.
• W347839190 hasConceptScore W347839190C2780192828 @default.
• W347839190 hasConceptScore W347839190C2780775027 @default.
• W347839190 hasConceptScore W347839190C2781406297 @default.
• W347839190 hasConceptScore W347839190C44249647 @default.
• W347839190 hasConceptScore W347839190C509974204 @default.
• W347839190 hasConceptScore W347839190C71924100 @default.
• W347839190 hasIssue "1" @default.
• W347839190 hasLocation W3478391901 @default.
• W347839190 hasLocation W3478391902 @default.
• W347839190 hasOpenAccess W347839190 @default.
• W347839190 hasPrimaryLocation W3478391901 @default.

• next